A Phase 1, Open-label, Single Dose Study To Evaluate The Effects Of Food And The Proton Pump Inhibitor, Esomeprazole, On The Pharmacokinetics Of Crizotinib In A Coated Microsphere Formulation In Adult Healthy Volunteers

Trial Profile

A Phase 1, Open-label, Single Dose Study To Evaluate The Effects Of Food And The Proton Pump Inhibitor, Esomeprazole, On The Pharmacokinetics Of Crizotinib In A Coated Microsphere Formulation In Adult Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Crizotinib (Primary) ; Esomeprazole
  • Indications Bladder cancer; Glioblastoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 08 Sep 2017 Planned primary completion date changed from 14 Sep 2017 to 17 Sep 2017.
    • 08 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top